Risk of intraocular hemorrhage among exudative age-related macular degeneration patients treated with different anti-VEGF agents
Min Seok Kim, Seonghee Nam, Jeongwoo Lee, Se Joon Woo · 2026
Read Risk of intraocular hemorrhage among exudative age-related macular degeneration patients treated with different anti-VEGF agents by Min Seok Kim, Seonghee Nam, Jeongwoo Lee, Se Joon Woo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0356596.txt.
Description
Min Seok Kim, Seonghee Nam, Jeongwoo Lee, and Se Joon Woo compared three injected eye drugs for a common blinding disease of older adults. Which carries the highest risk of serious internal bleeding? Their 2026 nationwide study used South Korean insurance records from 2014 to 2023. It followed patients newly treated for the wet form of age-related macular degeneration. The drugs were ranibizumab, aflibercept, and brolucizumab.
Bleeding severe enough to require surgical clearing was rare with all three drugs. But it occurred more often after brolucizumab and aflibercept than after ranibizumab. The authors caution that bleeding risk alone should not pick a patient's drug. The medicines differ in other ways. Still, the ranking gives doctors concrete numbers for counseling and for watching higher-risk patients closely.
Catalog record
| CREATOR | Min Seok Kim, Seonghee Nam, Jeongwoo Lee, Se Joon Woo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23855 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |